Anshuman Panda

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1397347/anshuman-panda-publications-by-year.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15	637	8	16
papers	citations	h-index	g-index
16 ext. papers	879 ext. citations	8.1 avg, IF	3.27 L-index

#	Paper	IF	Citations
15	A Gene Panel for Early Identification of Future Responders to Immune Checkpoint Blockade <i>Frontiers in Genetics</i> , 2022 , 13, 706468	4.5	
14	Recurring Translocations in Barretto Esophageal Adenocarcinoma. Frontiers in Genetics, 2021, 12, 6747	44 .5	2
13	Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer. <i>Frontiers in Genetics</i> , 2021 , 12, 706435	4.5	1
12	SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis. <i>Oncogene</i> , 2021 , 40, 6034-6048	3 9.2	O
11	Barrettos Epithelium to Esophageal Adenocarcinoma: Is There a "Point of No Return"?. <i>Frontiers in Genetics</i> , 2021 , 12, 706706	4.5	1
10	Tissue- and development-stage-specific mRNA and heterogeneous CNV signatures of human ribosomal proteins in normal and cancer samples. <i>Nucleic Acids Research</i> , 2020 , 48, 7079-7098	20.1	2
9	Genomic and immunologic correlates of LAG-3 expression in cancer. <i>Oncolmmunology</i> , 2020 , 9, 1756116	57.2	10
8	DNA hypomethylation promotes transposable element expression and activation of immune signaling in renal cell cancer. <i>JCI Insight</i> , 2020 , 5,	9.9	13
7	Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 316-320	9.7	113
6	Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. <i>JCI Insight</i> , 2018 , 3,	9.9	83
5	Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4804-4820	15.9	116
4	Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	28
3	Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma. <i>Scientific Reports</i> , 2017 , 7, 5568	4.9	21
2	Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. <i>Journal of Clinical Investigation</i> , 2016 , 126, 2334-40	15.9	239
1	The Modular Adaptive Ribosome. <i>PLoS ONE</i> , 2016 , 11, e0166021	3.7	8